APrevent Biotech GmbH news
AiSpeak is a technology relying on 5G network and AI machine learning. Its broad applications includes IoTs and audio for smart devices. Qualcomm is the global leader in these areas. We look forward to future collaboration and creating win-win relationships with Qualcomm.
APrevent VOIS has arrived in the UK market, starting in London metropolitan area.
In March we conducted VOIS cases in Guy’s Hospital (with Dr. Yakubu Karagama) and Charing Cross Hospital (with Dr. Chadwan Al-Yaghchi) respectively.
These are our very first cases in the United Kingdoms. We look forward to helping more patients in the UK.
Germany is one of the largest public healthcare spenders in the world. German NUB (Neue Untersuchungs- und Behandlungsmethode), which stands for New Methods of Treatment and Screening, is a payment scheme for remunerating cost-intensive "innovative" services and technologies that are used in addition to the procedures included in existing DRG-case payment and is only open to technologies/procedures that are considered "innovative and new" in Germany, with only 20% of all applicants receiving
APrevent announced on 17TH December that APrevent and hearLIFE signed the exclusive distribution agreement for APrevent® VOIS in Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Cambodia, Laos, Myanmar and Brunei. We are going to provide patients with glottic insufficiency/unilateral vocal fold paralysis an innovative, safe and effective surgical treatment.
hearLIFE Group has a wealth of professional experience in Korea and Southeast Asia and are familiar with product
APrevent announced on 7TH December that APrevent and Labostera signed the distribution agreement for APrevent® VOIS in Lithuania. We are going to provide patients with glottic insufficiency/unilateral vocal fold paralysis an innovative, safe and effective surgical treatment.
Labostera was founded in year 2005, they are experienced in ENT surgical products including surgical voice prosthesis, other surgical, ENT implants and equipme